Catalyst Wire Dossier Catalyst Wire Dossier

Casirivimab and Imdevimab (REGEN-COV)

casirivimab and imdevimab · Regeneron Pharmaceuticals
Drug timelines are a Plus or Pro feature.

2 regulatory and trial events tracked for Casirivimab and Imdevimab (REGEN-COV), covering 2023-02-21 to 2024-08-20. Get the full timeline:

Most recent: Clinical Trial Update: COVID-19 Study to Assess Immunogenicity, Safety, and Tolerability of Moderna mRNA-1273 Vaccine Administered With Casirivimab+Imdevimab in Healthy Adult Volunteers [Phase 2]

See pricing